View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 2, 2018updated 14 Nov 2021 1:13pm

OpGen to adopt Qiagen’s EZ1 instruments for AMR Gene Panel

Genomic analysis solutions provider OpGen has signed an agreement to leverage molecular diagnostics firm Qiagen’s EZ1 instruments in the test workflow of its Acuitas AMR Gene Panel u5.47 diagnostics.

Genomic analysis solutions provider OpGen has signed an agreement to leverage molecular diagnostics firm Qiagen’s EZ1 instruments in the test workflow of its Acuitas AMR Gene Panel u5.47 diagnostics.

The partners will use EZ1 Advanced XL automated nucleic acid purification instrumentation and kits to commercialise the antimicrobial resistant bacteria (AMR) diagnostics in the US.

AMR Gene Panel is a range of rapid diagnostics tests intended to detect and identify multidrug-resistant bacterial pathogens in urine and bacterial isolates in around two hours.

“The partners will use EZ1 Advanced XL automated nucleic acid purification instrumentation and kits to commercialise the antimicrobial resistant bacteria (AMR) diagnostics in the US.”

The panel can be used with the Acuitas Lighthouse Software to predict antibiotic resistance and for high-resolution pathogen tracking.

EZ1 is a class I medical device offering full automation with sample preparation throughput of up to 14 samples per one-hour run.

OpGen CEO and chairman Evan Jones said: “We are pleased to collaborate with Qiagen to further strengthen our AMR Gene Panel offering.

“The EZ1 provides best in class nucleic acid purification technology, and Qiagen’s extensive global commercial capabilities and diagnostic expertise should provide multiple opportunities for collaboration in the future.”

As part of the agreement, OpGen will purchase EZ1 instruments and reagent kits, and provide them to US customers for use with its Acuitas AMR Gene Panel.

Qiagen Molecular Diagnostics business area senior vice-president Thierry Bernard said: “The partnership further expands the menu for EZ1 and adds a new and rapid diagnostic solution in the crucial fight against AMR.”

Last month, Qiagen introduced a next-generation, fully integrated molecular analysis panel in Europe to diagnose gastrointestinal (GI) syndromes. The panel is designed to detect 24 of the most common viral, bacterial and parasitic pathogens that cause GI infections.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network